Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions

Keck, Bastian; Borkowetz, Angelika; Poellmann, Julia; Jansen, T. S.; Fischer, M.A.; Fuessel, Susanne; Kahlmeyer, Andreas; Wirth, Manfred P.; Huber, Johannes; Cavallaro, Alexander; Hammon, Matthias; Platzek, Ivan; Hartmann, Arndt; Baretton, Gustavo; Kunath, Frank; Sikic, Danijel; Täubert, Helge; Wullich, Bernd; Erdmann, Kati; Wach, Sven

doi:10.3390/cells10061315

Cited by 6 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously reported on GP88 protein as a prognostic factor for PCa patients based on the detection of serum levels or in tumor tissue by IHC [ 21 , 26 ]. Furthermore, miR-486 serum levels supported the indication for MRI-ultrasound fusion-guided biopsy of the prostate in PCa patients with low-PI-RADS lesions [ 12 ]. Based on these results, we studied the levels of GP88 and miR-486 in the serum of PCa patients, correlated them with clinicopathological parameters, and investigated whether these parameters could be indicative of the therapy intention of active surveillance or definitive curative treatment in PCa.…”

Section: Discussionmentioning

confidence: 99%

“…MiR-486 has been identified as a TP53-induced miRNA that can repress the mRNA expression of citron rho-interacting serine/threonine kinase (CIT) [ 44 ], which is associated with high expression and poor prognosis in PCa patients [ 45 ]. In our previous study, lower expression levels of miR-486 and let-7c together with clinical parameters in a model helped to better identify clinically significant PCa [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNAs are small non-coding RNAs that have been described as tumor suppressors or oncogenes in different cancers, including prostate cancer [ 9 , 10 , 11 ]. In a previous study, we analyzed a selected set of seven miRNAs in combination with clinical and mpMRI information for PCa prediction and classification [ 12 ]. The addition of miR-486 and let-7c expression to the baseline model that exclusively included clinical parameters increased the predictive accuracy to identify clinically significant PCa [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Fichte

Neumann

Weigelt

et al. 2022

Life

Self Cite

View full text Add to dashboard Cite

Our study aimed to assess the applicability of miR-486 in combination with soluble GP88 protein as a diagnostic and/or predictive biomarker for prostate cancer (PCa) patients. miR-486 and GP88 levels in serum samples from 136 patients undergoing MRI-guided biopsy of the prostate were assessed by qRT–PCR and ELISA, respectively. Of these, 86 patients received a histologically confirmed diagnosis of PCa. Neither marker showed an association with the diagnosis of cancer. PCa patients were separated based on (i) treatment into patients with active surveillance or patients with any type of curative treatment and (ii) age into elderly (>68 years) patients and younger patients (≤68 years). In elderly patients (N = 41) with the intention of curative treatment at optimized cut-off values, significantly higher GP88 levels (p = 0.018) and lower miR-486 levels (p = 0.014) were observed. The total PSA level and ISUP biopsy grade were used in a baseline model for predicting definitive therapy. The baseline model exhibited an area under the curve (AUC) of 0.783 (p = 0.005). The addition of the serum biomarkers miR-486 and GP88 to the baseline model yielded an improved model with an AUC of 0.808 (p = 0.002). Altogether, combined miR-486 and GP88 serum levels are associated with and are therefore suggested as supportive biomarkers for therapy decisions, particularly in elderly PCa patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Fichte

Neumann

Weigelt

et al. 2022

Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…16,19,20,26,28,30,36,81 No potential source of bias was identified for the other 64 (89%) studies. [10][11][12][13][14][15]17,18,[21][22][23][24][25]27,29,[31][32][33][34][35] Retrospective study design and concern regarding the selection domain (ie, studies only noted that patients with suspected csPCa were included rather than providing detailed inclusion and/or exclusion criteria)…”

Section: Quality Assessment and Publication Biasmentioning

confidence: 99%

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer

Haj-Mirzaian,

Burk,

Lacson

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceMultiple strategies integrating magnetic resonance imaging (MRI) and clinical data have been proposed to determine the need for a prostate biopsy in men with suspected clinically significant prostate cancer (csPCa) (Gleason score ≥3 + 4). However, inconsistencies across different strategies create challenges for drawing a definitive conclusion.ObjectiveTo determine the optimal prostate biopsy decision-making strategy for avoiding unnecessary biopsies and minimizing the risk of missing csPCa by combining MRI Prostate Imaging Reporting &amp; Data System (PI-RADS) and clinical data.Data SourcesPubMed, Ovid MEDLINE, Embase, Web of Science, and Cochrane Library from inception to July 1, 2022.Study SelectionEnglish-language studies that evaluated men with suspected but not confirmed csPCa who underwent MRI PI-RADS followed by prostate biopsy were included. Each study had proposed a biopsy plan by combining PI-RADS and clinical data.Data Extraction and SynthesisStudies were independently assessed for eligibility for inclusion. Quality of studies was appraised using the Quality Assessment of Diagnostic Accuracy Studies 2 tool and the Newcastle-Ottawa Scale. Mixed-effects meta-analyses and meta-regression models with multimodel inference were performed. Reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline.Main Outcomes and MeasuresIndependent risk factors of csPCa were determined by performing meta-regression between the rate of csPCa and PI-RADS and clinical parameters. Yields of different biopsy strategies were assessed by performing diagnostic meta-analysis.ResultsThe analyses included 72 studies comprising 36 366 patients. Univariable meta-regression showed that PI-RADS 4 (β-coefficient [SE], 7.82 [3.85]; P = .045) and PI-RADS 5 (β-coefficient [SE], 23.18 [4.46]; P &lt; .001) lesions, but not PI-RADS 3 lesions (β-coefficient [SE], −4.08 [3.06]; P = .19), were significantly associated with a higher risk of csPCa. When considered jointly in a multivariable model, prostate-specific antigen density (PSAD) was the only clinical variable significantly associated with csPCa (β-coefficient [SE], 15.50 [5.14]; P &lt; .001) besides PI-RADS 5 (β-coefficient [SE], 9.19 [3.33]; P &lt; .001). Avoiding biopsy in patients with lesions with PI-RADS category of 3 or less and PSAD less than 0.10 (vs &lt;0.15) ng/mL2 resulted in reducing 30% (vs 48%) of unnecessary biopsies (compared with performing biopsy in all suspected patients), with an estimated sensitivity of 97% (vs 95%) and number needed to harm of 17 (vs 15).Conclusions and RelevanceThese findings suggest that in patients with suspected csPCa, patient-tailored prostate biopsy decisions based on PI-RADS and PSAD could prevent unnecessary procedures while maintaining high sensitivity.

show abstract

“…Three putative normalizers (miR-16, miR-191 and miR-103) which were searched through literature review were tested for use in EVs from patients with prostate disease [23,24]. Samples were recruited randomly and consecutively and then divided into a group with BPH (8 patients) and the other group with prostate cancer (9 patients) to find the most stable reference.…”

Section: Determination Of Endogenous Normalizers By Normfinder Algorithmmentioning

confidence: 99%

Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer

et al. 2021

View full text Add to dashboard Cite

Extracellular vesicles (EVs) contain various types of molecules including micro-RNAs, so isolating EVs can be an effective way to analyze and diagnose diseases. A lot of micro-RNAs have been known in relation to prostate cancer (PCa), and we evaluate miR-21, miR-141, and miR-221 in EVs and compare them with prostate-specific antigen (PSA). EVs were isolated from plasma of 38 patients with prostate cancer and 8 patients with benign prostatic hyperplasia (BPH), using a method that showed the highest recovery of RNA. Isolation of EVs concentrated micro-RNAs, reducing the cycle threshold (Ct) value of RT-qPCR amplification of micro-RNA such as miR-16 by 5.12 and miR-191 by 4.65, compared to the values before EV isolation. Normalization of target micro-RNAs was done using miR-191. For miR-221, the mean expression level of patients with localized PCa was significantly higher than that of the control group, having 33.45 times higher expression than the control group (p < 0.01). Area under curve (AUC) between BPH and PCa for miR-221 was 0.98 (p < 0.0001), which was better than AUC for prostate-specific antigen (PSA) level in serum for the same patients. The levels of miR-21 and miR-141 in EVs did not show significant changes in patients with PCa compared to the control group in this study. This study suggests isolating EVs can be a helpful approach in analyzing micro-RNAs with regard to disease.

show abstract

Serum miRNAs Support the Indication for MRI-Ultrasound Fusion-Guided Biopsy of the Prostate in Patients with Low-PI-RADS Lesions

Cited by 6 publications

References 33 publications

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer

Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer

Contact Info

Product

Resources

About